ScripAmid an ongoing capital crunch, Chinese drug makers pursuing in-licensing models have arrived at a commercialization crossroads. Jump-started by frontrunner Zai Lab Ltd. ’s successful introduction of
In VivoA beneficial effect of sponsorship by the largest companies in the pharma industry can be seen in the fates of novel agent applications that faced US FDA approval decisions in recent years: the applic
Pink SheetA beneficial effect of sponsorship by the largest companies in the pharma industry can be seen in the fates of novel agent applications that faced US FDA approval decisions in recent years: the applic
ScripJust five months after bagging US rights to Provention Bio, Inc. 's type 1 diabetes therapy Tzield, Sanofi has decided it wants to buy the whole company and is prepared to pay a huge premium to do